Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR1701 + SHR2554 + capecitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is a multi-drug regimen being investigated for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma. It consists of SHR1701, a bifunctional fusion protein that simultaneously targets Programmed cell death 1 ligand 1 (PD-L1) and Transforming growth factor beta (TGF-β); SHR2554, a small-molecule inhibitor of Histone-lysine N-methyltransferase EZH2; and the CAPOX chemotherapy regimen, which includes capecitabine and oxaliplatin. The rationale for this combination is to leverage the synergistic effects of immune checkpoint blockade, TGF-β inhibition, and epigenetic modulation to overcome primary and acquired resistance to standard immunotherapy and chemotherapy in gastric cancer patients.
- Other names
- SHR1701 + SHR2554 + CAPOX
02
Targets
DNAEZH1EZH2 (Histone-lysine N-methyltransferase EZH2)CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)TS (Thymidylate synthase)
Beyond the preview
Go deeper on SHR1701 + SHR2554 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR1701 + SHR2554 + capecitabine + oxaliplatin.